PROTON PARTNERS INTERNATIONAL LIMITED, which is planning to build three proton beam therapy cancer treatment centers in the U.K., announced the appointment of global partners to provide clinical equipment and technology solutions to the company.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
